Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55-7. doi: 10.1097/QAI.0b013e31827ca50f.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aspartate Aminotransferases / blood
  • Chemical and Drug Induced Liver Injury / blood
  • Chemical and Drug Induced Liver Injury / genetics*
  • Cytochrome P-450 CYP2B6
  • Double-Blind Method
  • Female
  • Genotype
  • HIV Infections / drug therapy*
  • HLA-B Antigens / genetics*
  • HLA-DRB1 Chains / genetics
  • Humans
  • Male
  • Multivariate Analysis
  • Nevirapine / adverse effects*
  • Nevirapine / therapeutic use
  • Oxidoreductases, N-Demethylating / genetics
  • Phenotype
  • Reverse Transcriptase Inhibitors / therapeutic use
  • South Africa

Substances

  • Anti-HIV Agents
  • HLA-B Antigens
  • HLA-B*58:01 antigen
  • HLA-DRB1 Chains
  • Reverse Transcriptase Inhibitors
  • Nevirapine
  • Aryl Hydrocarbon Hydroxylases
  • CYP2B6 protein, human
  • Cytochrome P-450 CYP2B6
  • Oxidoreductases, N-Demethylating
  • Aspartate Aminotransferases
  • Alanine Transaminase